Mycophenolate Mofetil in C3 Glomerulopathy and Pathogenic Drivers of the Disease.

ABSTRACT:

Background and objectives

C3 glomerulopathy is a complement-mediated disease arising from abnormalities in complement genes and/or antibodies against complement components. Previous studies showed that treatment with corticosteroids plus mycophenolate mofetil (MMF) was associated with improved outcomes, although the genetic profile of these patients was not systematically analyzed. This study aims to analyze the main determinants of disease progression and response to this therapeutic regimen.

Design, setting, participants, & measurements

We conducted a retrospective, multicenter, observational cohort study in 35 nephrology departments belonging to the Spanish Group for the Study of Glomerular Diseases. Patients diagnosed with C3 glomerulopathy (n=81) or dense deposit

SUBMITTER: Caravaca-Fontan F 

PROVIDER: S-EPMC7480558 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature